Vifor Pharma
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
* | $11.7b Valuation: $11.7b 8.0x EV/Revenue 23.3x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 18 % | 18 % | (9 %) | 3 % | 12 % | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 21 % | 25 % | 29 % | 34 % | 34 % | 35 % | 36 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 85 % | 10 % | 8 % | 21 % | 15 % | 15 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 14 % | 14 % | 13 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Vifor Pharma's journey began in 1872, originally as part of the Galenica Group in Switzerland. Over the years, it evolved into a global pharmaceutical company, specializing in iron deficiency, kidney diseases, and cardio-renal syndromes. The company's focus on these niche areas allowed it to develop and commercialize late-stage medicines that significantly impacted treatment paradigms.
In a significant milestone, Vifor Pharma underwent a major transformation when it was acquired by CSL Limited in 2022. This acquisition, valued at $11.7 billion, marked a new chapter for Vifor Pharma, integrating it into CSL's expansive global network. The acquisition was a strategic move to enhance CSL's portfolio in the specialty pharmaceuticals sector, particularly in areas where Vifor had established expertise.
Throughout its history, Vifor Pharma has been recognized for its commitment to innovation and patient care. The company's ability to adapt and grow in the competitive pharmaceutical landscape underscores its resilience and forward-thinking approach. Today, as part of CSL, Vifor Pharma continues to build on its legacy, contributing to advancements in healthcare and improving patient outcomes worldwide.
